| Q51540637 | A cocaine-positive baseline urine predicts outpatient treatment attrition and failure to attain initial abstinence. |
| Q46086545 | A county survey of mental health services in drug treatment programs |
| Q36794579 | A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders |
| Q44836258 | A replicable model for achieving over 90% follow-up rates in longitudinal studies of substance abusers |
| Q33718249 | A two-level structural equation model approach for analyzing multivariate longitudinal responses |
| Q24635217 | An examination of psychiatric comorbidities as a function of gender and substance type within an inpatient substance use treatment program |
| Q47645212 | An examination of the cocaine relapse process |
| Q35174572 | Anxiety disorders among methamphetamine dependent adults: association with post-treatment functioning |
| Q36973596 | Application of the Transtheoretical Model of change: psychometric properties of leading measures in patients with co-occurring drug abuse and severe mental illness |
| Q35880533 | Axis I and II disorders as long-term predictors of mental distress: a six-year prospective follow-up of substance-dependent patients |
| Q40765113 | Baseline prediction of 7-month cocaine abstinence for cocaine dependence patients |
| Q35040066 | Brief screening for co-occurring disorders among women entering substance abuse treatment |
| Q43890379 | Changes in use of crack cocaine after drug misuse treatment: 4-5 year follow-up results from the National Treatment Outcome Research Study (NTORS). |
| Q34044792 | Cocaine Dependence Treatment Data: Methods for Measurement Error Problems With Predictors Derived From Stationary Stochastic Processes |
| Q53616564 | Cocaine-using substance abuse treatment patients with and without HIV respond well to contingency management treatment. |
| Q36813681 | Cognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders |
| Q40518071 | Comparison of pretreatment characteristics and treatment outcomes for alcohol-, cocaine-, and multisubstance-dependent patients |
| Q52279531 | Coping style of substance-abuse patients: effects of anxiety and mood disorders on coping change. |
| Q37292458 | Correlates of stimulant treatment outcome across treatment modalities |
| Q43564570 | Crack cocaine--a two-year follow-up of treated patients |
| Q37359054 | Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up |
| Q43757607 | Depression among needle exchange program and methadone maintenance clients |
| Q36700853 | Development and initial evaluation of the Brief Addiction Monitor (BAM). |
| Q36478373 | Effects of major depressive disorder and attention-deficit/hyperactivity disorder on the outcome of treatment for cocaine dependence |
| Q51099160 | Effects of naltrexone on cue-elicited craving for alcohol and cocaine. |
| Q36966700 | Factors in sustained recovery from cocaine dependence |
| Q44689735 | Followup of cocaine-dependent men and women with antisocial personality disorder |
| Q34193693 | Hippocampal volume mediates the relationship between measures of pre-treatment cocaine use and within-treatment cocaine abstinence |
| Q35865541 | Impact of program services on treatment outcomes of patients with comorbid mental and substance use disorders |
| Q45263972 | Improving service delivery to the dually diagnosed in Los Angeles County |
| Q34977212 | Intravenous and non-intravenous cocaine abusers admitted to inpatient detoxification treatment: a 3-year medical-chart review of patient characteristics and predictors of treatment re-admission. |
| Q34012500 | Meta-analysis of depression and substance use and impairment among cocaine users |
| Q44347699 | Naltrexone pharmacotherapy for opioid dependent federal probationers |
| Q51538883 | Neuropsychological differences between alcohol-dependent and cocaine-dependent patients with or without problematic drinking. |
| Q34971483 | On beyond urine: clinically useful assessment instruments in the treatment of drug dependence. |
| Q38189640 | On the interaction between drugs of abuse and adolescent social behavior. |
| Q40757707 | One-year outcome of adolescent females referred for conduct disorder and substance abuse/dependence |
| Q28183554 | Patterns and correlates of Gamblers Anonymous attendance in pathological gamblers seeking professional treatment |
| Q45109171 | Perinatal substance abusers: factors influencing treatment retention |
| Q34982551 | Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine |
| Q34253787 | Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate. |
| Q78170781 | Predicting proximal factors in cocaine relapse and near miss episodes: clinical and theoretical implications |
| Q44094307 | Predicting treatment success at multiple timepoints in diverse patient populations of cocaine-dependent individuals |
| Q44071086 | Predicting treatment-outcome in cocaine dependence from admission urine drug screen and peripheral serotonergic measures |
| Q44344111 | Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence |
| Q77462288 | Predictors of dropout from psychosocial treatment of cocaine dependence |
| Q33912719 | Predictors of longitudinal substance use and mental health outcomes for patients in two integrated service delivery systems |
| Q36085088 | Predictors of time to relapse in amphetamine-type substance users in the matrix treatment program in Iran: a Cox proportional hazard model application |
| Q34675579 | Prevalence and socio-demographic risk factors associated with psychoactive substance use in psychiatric out-patients of a tertiary hospital in Nigeria |
| Q37005440 | Prize reinforcement contingency management for treating cocaine users: how low can we go, and with whom? |
| Q33967732 | Psychiatric Symptom Improvement in Women Following Group Substance Abuse Treatment: Results from the Women's Recovery Group Study |
| Q51994399 | Psychiatric symptom severity in cocaine-dependent outpatients: demographics, drug use characteristics and treatment outcome. |
| Q37168175 | Psychopathology in methamphetamine-dependent adults 3 years after treatment |
| Q34567589 | Psychosocial treatments for cocaine dependence: The role of depressive symptoms |
| Q73357036 | Psychosocially enhanced treatment for cocaine-dependent mothers: evidence of efficacy |
| Q34742035 | Quality of life, depression, anxiety and suicidal ideation among men who inject drugs in Delhi, India |
| Q35781994 | Regardless of psychiatric severity the addition of contingency management to standard treatment improves retention and drug use outcomes |
| Q44380074 | Relationship between platelet serotonin uptake sites and treatment outcome among African-American cocaine dependent individuals |
| Q31926065 | Results of a baseline urine test predict levels of cocaine use during treatment |
| Q44829771 | Screening for psychiatric disorders in outpatients with DSM-IV substance use disorders |
| Q91557400 | Sequential cocaine-alcohol self-administration produces adaptations in rat nucleus accumbens core glutamate homeostasis that are distinct from those produced by cocaine self-administration alone |
| Q36712877 | Substance dependence and remission in schizophrenia: A comparison of schizophrenia and affective disorders |
| Q64980809 | Symptoms of anhedonia, not depression, predict the outcome of treatment of cocaine dependence. |
| Q52221619 | The autonomy of mood disorders among cocaine-using methadone patients. |
| Q39555493 | The effectiveness of two intensities of psychosocial treatment for cocaine dependence |
| Q28369822 | The effects of naltrexone on alcohol and cocaine use in dually addicted patients |
| Q37078032 | The impact of cigarette smoking on stimulant addiction |
| Q36752077 | The impact of contingency management on quality of life among cocaine abusers with and without alcohol dependence |
| Q36384712 | The impact of disulfiram treatment on the reinforcing effects of cocaine: a randomized clinical trial |
| Q51719318 | The interaction of co-occurring mental disorders and recovery management checkups on substance abuse treatment participation and recovery. |
| Q41127953 | The management of treatment resistance in depressed patients with substance use disorders |
| Q31132188 | The role of stress in addiction relapse |
| Q51538773 | Treatment outcome of cocaine-alcohol dependent patients. |
| Q44413205 | Treatment utilization and personality organization among drug abusers in Sweden |
| Q37273932 | Use of stimulants to treat cocaine and methamphetamine abuse. |
| Q28373224 | Venlafaxine treatment of cocaine abusers with depressive disorders |
| Q33740800 | Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management? |